Announcements from Department of Health
30 . 10 . 2024
Please note the following announcement from Department of Health:
- Summary Safety Review - Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the potential risks of prolonged or incident diabetic ketoacidosis despite stopping treatment in adult patients with type 2 diabetes
- Plaquenil (Hydroxychloroquine sulfate): Risk of major congenital malformations and new risks of phospholipidosis and aggravation of myasthenia gravis symptoms
- Lunsumio (mosunetuzumab): New important identified risk of Hemophagocytic Lymphohistiocytosis